TB Alliance ZeNix trial

TB Alliance ZeNix trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB

TB Alliance ZeNix trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB

ZeNix trial in South Africa and Eastern Europe sought to optimize the 6-month treatment regimen with reduced exposure to the drug linezolid India has the leading number of TB cases globally New Delhi/Berlin/Pretoria, July 16: The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid-associated side effects. The results from…
Read More